Leipzig, Germany – “The aim of our multidisciplinary and broad-based project is to establish antimicrobial stewardship in sub-Saharan Africa and to prevent the transmission of infectious diseases through a One Health approach,” says Dr Ahmed Abd El Wahed. Research institutions from the seven countries involved in this network – Uganda,...
research News
Baltimore, Maryland – Age-related changes that cause the skin to stiffen and become less elastic may also contribute to higher rates of metastatic skin cancer in older people, according to research by investigators from the Johns Hopkins Kimmel Cancer Center. The study, published March 12 in Nature Aging, shows that increased...
Cambridge, Mass. – Rare disease company Agios Pharmaceuticals reached the primary endpoint in a Phase III study for its drug pyrukynd (mitapivat) in adults with non-transfusion-dependent alpha- or beta-thalassemia, according to the company’s announcement on Wednesday The Phase III ENERGIZE study met the primary endpoint of hemoglobin response, defined as...
Changchun, China – Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is a major global health concern with rising rates, particularly in North Africa and East Asia. Although potentially curable in the early stages, HCC often remains undetected until it’s too late for effective treatment. This...
Palo Alto, Calif. – Using novel machine learning tools developed at Stanford Medicine, researchers have mapped three distinct cellular configurations that correspond to clinical outcomes for patients with a rare, difficult-to-treat cancer called soft tissue sarcoma. In particular, the technique identified a cellular neighborhood that correlated with a positive response...
SEOUL, South Korea — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of six studies at the upcoming SITC (Society for Immunotherapy of Cancer) 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California. During this year’s...
OCALA, Fla. — AIM ImmunoTech Inc., today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”). Data strongly suggests...
Rockville, MD – AIM-HI Accelerator Fund is proud to celebrate a significant milestone in the journey of one of its esteemed portfolio companies, Yiviva. A clinical-stage platform biotechnology company, Yiviva has entered into a Memorandum of Understanding (MOU) with AstraZeneca China, a multinational biopharmaceutical leader. AIM-HI was established with a...
HONG KONG — Akeso Inc. announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with chemotherapy in the first-line treatment for patients with PD-L1 negative (PD-L1 TPS<1%) non-small cell lung cancer (NSCLC)...
HONG KONG — Akeso, Inc. today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mid- and advanced-stage hepatocellular carcinoma (HCC) in a poster at the 2024 American Society of Clinical Oncology...